Disease-state leukopaks are effective surrogates for establishing cell therapy manufacturing parameters.

Leukopaks from patients provide large pools of PBMCs.

Immunogenicity biomarkers in individuals previously infected with COVID-19 were used to evaluate vaccines in preclinical and clinical trials.

A specific autoimmune indication was identified for a novel therapy using patient donor biospecimens.

A prospective, longitudinal study using in-home collected biospecimens identified a panel of predictive biomarkers.